Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (3.922.231 €): Maschinelles Lernen Computational Advances für peRsonalized mEdicine Hor27.06.2025 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Maschinelles Lernen Computational Advances für peRsonalized mEdicine
Personalized medicine represents a paradigm shift in healthcare, transitioning from generalized treatment strategies to highly personalized care. This transformation is driven by rapid advancements in digital technologies, which generate massive volumes of data from diverse sources, including genomic sequences, high-resolution imaging, wearable devices, and electronic health records (EHRs). However, despite an annual estimate of 50 petabytes of data generated per hospital, only a fraction is utilized effectively. Harnessing this untapped potential offers a transformative opportunity to uncover novel disease mechanisms and deliver more precise and effective therapeutic interventions. The MLCARE project seeks to revolutionize personalized medicine by developing cutting-edge AI solutions that integrate genomic, clinical, and environmental data into holistic, multimodal patient representations. Through innovative approaches such as Foundation Models and advanced generative AI methods, MLCARE will address critical challenges in processing complex, high-dimensional, and multimodal datasets. Emphasis will be placed on ensuring the trustworthiness, explainability, and security of AI applications to support real-world clinical decision-making. A core mission of MLCARE is to train a new generation of interdisciplinary researchers with expertise spanning AI, computational biology, and healthcare. The program will equip doctoral candidates with the technical, analytical, and ethical skills needed to lead the future of patient-centered, AI-driven medicine. By combining state-of-the-art research with a comprehensive training program, MLCARE aims to set new standards in personalized healthcare, ensuring equitable, data-driven solutions that improve outcomes across diverse populations. This project is poised to position Europe at the forefront of global innovation in precision medicine, delivering a timely and impactful response to evolving healthcare challenges.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Astrazeneca Farmaceutica Spain SA | ? |
| Astrazeneca UK Ltd. | 348.738 € |
| Fundacion Publica Andaluza Progreso y Salud M.P | 282.188 € |
| HMNC HOLDING GmbH | 290.272 € |
| Kobenhavns Universitet | 335.890 € |
| LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN | 580.545 € |
| MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN e. V. | 290.272 € |
| Pharmatics Ltd. | 348.738 € |
| TARTU ULIKOOL | 278.002 € |
| Universidad Carlos III de Madrid | 564.376 € |
| Universite de Liege | 288.540 € |
| Universite Paris Cite | 314.669 € |
Quelle: https://cordis.europa.eu/project/id/101226456
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der aktuelle Stand wird auf folgender Seite wiedergegeben: Astrazeneca Farmaceutica Spain SA, Madrid, Spanien.
Die Visualisierungen zu "Astrazeneca Farmaceutica Spain SA - EU-Förderung (3.922.231 €): Maschinelles Lernen Computational Advances für peRsonalized mEdicine"
werden von
North Data
zur Weiterverwendung unter einer
Creative Commons Lizenz
zur Verfügung gestellt.
